{"resourceType": "Library", "id": "179618", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-included-studies"], "versionId": "3", "lastUpdated": "2023-11-26T21:01:14.757Z"}, "url": "https://fevir.net/resources/Library/179618", "title": "SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer", "status": "active", "type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/library-type", "code": "asset-collection", "display": "Asset Collection"}]}, "subjectReference": {"reference": "Group/179619", "type": "Group", "display": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"}, "date": "2023-11-26T18:15:27.442Z", "publisher": "Computable Publishing LLC", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "description": "3 included studies", "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "SystematicReviewIncludedStudies", "display": "SystematicReviewIncludedStudies"}]}}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "relatedArtifact": [{"type": "derived-from", "resourceReference": {"reference": "Citation/179613", "type": "Citation", "display": "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."}}, {"type": "contains", "resourceReference": {"reference": "Citation/179615", "type": "Citation", "display": "23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial."}}, {"type": "contains", "resourceReference": {"reference": "Citation/179617", "type": "Citation", "display": "25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the 'Docetaxel Era': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)."}}, {"type": "contains", "resourceReference": {"reference": "Citation/179616", "type": "Citation", "display": "26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer."}}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net/FOI", "value": "179618", "assigner": {"display": "Computable Publishing LLC"}}], "author": [{"name": "Brian S. Alper"}], "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "code": "active", "display": "Active"}]}}]}